Cost-effectiveness of newer antidepressants compared with tricyclic antidepressants in managed care settings

Journal of Clinical Psychiatry

Volumn 58, Issue 2, 1997, Pages 47-58

  Revicki, Dennis A ^a   Brown, Ruth E ^a   Keller, Martin B ^b   Gonzales, Junius ^c   Culpepper, Larry ^b   Hales, Robert E ^d  

^a UNITED BIOSOURCE CORPORATION   (United States)

^b BROWN UNIVERSITY   (United States)

^c GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; FLUOXETINE; IMIPRAMINE; NEFAZODONE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DRUG COST; DRUG INDUCED DISEASE; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MANAGED CARE; MEDICAL DECISION MAKING; MENTAL DISEASE; PATIENT COMPLIANCE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; SUICIDE; TREATMENT OUTCOME;

EID: 0031034863     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v58n0201     Document Type: Article

References (65)

1. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the national comorbidity survey. Arch Gen Psychiatry 1994;51:8-19
2. Schulberg HC, Burns BJ. Mental disorders in primary care: epidemiologic, diagnostic, and treatment research directions. Gen Hosp Psychiatry 1988;10:79-87
3. Barrett JE, Barrett JA, Oxman TE, et al. The prevalence of psychiatric disorders in a primary care practice. Arch Gen Psychiatry 1988;45: 1100-1106
4. Wells KB, Stewart A, Hays RD, et al. The functioning and well-being of depressed patients: results from the Medical Outcomes Study. JAMA 1989;262:916-919
5. Johnson J, Weissman MN, Klerman GL. Service utilization and social morbidity associated with depressive symptoms in the community. JAMA 1992;267:1478-1483
6. Broadhead EW, Blazer DG, George LK, et al. Depression, disability days and days lost from work in a prospective epidemiologic survey. JAMA 1990;264:2524-2528
7. Greenberg PE, Stiglin LE, Finkelstein SN, et al. The economic burden of depression in 1990. J Clin Psychiatry 1993;54:405-418
8. Wells KB, Hays RD, Burnam MA, et al. Detection of depressive disorder for patients receiving prepaid or fee-for-service care: results from the Medical Outcomes Study. JAMA 1989;262:3298-3302
9. Perez-Stable EJ, Miranda J, Munoz RF, et al. Depression in medical outpatients: underrecognition and misdiagnosis. Arch Intern Med 1990; 150:1083-1088
10. Ormel J, Koeter MWJ, van den Brink W, et al. Recognition, management, and the course of anxiety and depression in general practice. Arch Gen Psychiatry 1991;48:700-706
11. Johnson DAW. A study of the use of antidepressant medication in general practice. Br J Psychiatry 1974;125:186-192
12. Katon W, VonKorff M, Lin E, et al. Adequacy and duration of antidepressant treatment in primary care. Med Care 1992;30:67-76
13. Simon GE, VonKorff M, Wagner EH, et al. Patterns of antidepressant use in community practice. Gen Hosp Psychiatry 1993;15:399-408
14. Potter WZ, Rudorfer MV, Manji H. The pharmacologic treatment of depression. N Engl J Med 1991;325:633-642
15. Baldessarini RJ. Current status of antidepressants: clinical pharmacology and therapy [Festschrift article]. J Clin Psychiatry 1989;50:117-126
16. Depression Guideline Panel. Depression in Primary Care, Vol 2: Treatment of Major Depression. Clinical Practice Guideline, Number 5. Rockville, Md: US Dept Health and Human Services, Public Health Service, Agency for Health Care Policy and Research. AHCPR Publication No. 93-0551, April 1993
17. Montgomery SA, Dufour H, Brion S. et al. The prophylactic efficacy of fluoxetine and unipolar depression. Br J Psychiatry 1988;153(suppl 3): 69-76
18. Stark P, Hardison CD. A review of multicenter controlled studies of fluoxetine vs imipramine and placebo in outpatients with major depressive disorder. J Clin Psychiatry 1985;46(3, sec 2):53-58
19. Doogan DP, Caillard V. Sertraline: a new antidepressant. J Clin Psychiatry 1988;49(8 suppl):46-51
20. Doogan DP, Caillard V. Sertraline in the prevention of depression. Br J Psychiatry 1992;160:217-222
21. Song F, Freemantle N, Sheldon T. et al. Selective serotonin reuptake inhibitors: meta-analysis of efficacy and acceptability. BMJ 1993;306: 683-687
22. Feighner JP, Pambakian R, Fowler RC, et al. A comparison of nefazodone, imipramine, and placebo in patients with moderate to severe depression. Psychopharmacol Bull 1989;25:219-221
23. Rickels S, Schweizer E, Clary C, et al. Nefazodone and imipramine in major depression: a placebo-controlled trial. Br J Psychiatry 1994;164: 802-805
24. Fontaine R, Ontiveros A, Elie R, et al. Double-blind comparison of nefazodone, imipramine, and placebo in major depression. J Clin Psychiatry 1994;55:234-241
25. Mendels J, Reimherr F, Marcus RN, et al. A double-blind, placebo-controlled trial of two dose ranges of nefazodone in the treatment of depressed outpatients. J Clin Psychiatry 1995;56(6, suppl):30-36
26. Anton SF, Robinson DS, Roberts DL, et al. Long-term treatment with nefazodone. Psychopharmacol Bull 1994;30:165-169
27. Preskorn SH. Comparison of the tolerability of bupropion, fluoxetine, imipramine, nefazodone, paroxetine, sertraline, and venlafaxine. J Clin Psychiatry 1995;56(suppl6):12-21
28. Drummond MF, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmers. Oxford, England: Oxford University Press; 1987
29. Eisenberg J. Clinical economics: a guide to the economic analysis of clinical practices. JAMA 1989;262:2879-2886
30. Kamlet MS, Paul N, Greenhouse J, et al. Cost utility analysis of maintenance treatment for recurrent depression. Control Clin Trials 1995;16: 17-40
31. Hatziandreu EJ, Brown RE, Revicki DA, et al. Cost-utility of maintenance treatment for recurrent depression with sertraline versus episodic treatment with dothiepin. Pharmacoeconomics 1994;5:249-264
32. Jonsson B, Bebbington P. What price depression: the cost of depression and the cost-effectiveness of pharmacologic treatment. Br J Psychiatry 1994;164:665-673
33. Anton S, Revicki DA. The use of decision analysis in the pharmacoeconomic evaluation of an antidepressant: cost-effectiveness study of nefazodone. Psychopharmacol Bull 1995;31:249-258
34. Revicki DA, Brown RE, Palmer W, et al. Modelling the cost-effectiveness of antidepressant treatment in primary care. Pharmacoeconomics 1995;8: 524-540
35. Stewart A. Antidepressant pharmacotherapy: cost comparison of SSRIs and TCAs. British Journal of Medical Economics 1994;7:67-79
36. Revicki DA, Luce BR. Methods of pharmacoeconomic evaluation of new medical treatments in psychiatry. Psychopharmacol Bull 1995;31:57-65
37. Simon GE, Wagner E, VonKorff M. Cost-effectiveness comparisons using "real world" randomized trials: the case of new antidepressants. J Clin Epidemiol 1995;48:363-373
38. Weinstein MC, Fineberg HV. Clinical Decision Analysis. Philadelphia, Pa: Saunders; 1980
39. Pauker SG, Kassirer JP. Medical progress-decision analysis. N Engl J Med 1987;316:250-258
40. Sonnenberg FA, Roberts MS, Tsevat J, et al. Toward a peer review process for medical decision analysis models. Med Care 1994;32:JS52-JS64
41. Fink A, Kosecoff J, Chassin M, et al. Consensus methods: characteristics and guidelines for use. Am J Public Health 1984;74:979-983
42. Basco MR. Treatment adherence in mood disorders. Dallas, Tex: Department of Psychiatry, University of Texas Southwestern Medical Center; July 1993
43. Simon G, Vonkorff M, Heiligenstein J, et al. Initial antidepressant treatment in primary care: effectiveness and cost of fluoxetine vs tricyclic antidepressants. JAMA 1996;275:1897-1902
44. Lin EHB, VonKorff M, Katon W, et al. The role of the primary care physician in patients' adherence to antidepressant therapy. Med Care 1995;33: 67-74
45. Blackwell B. The drug regimen and treatment compliance. In: Taylor DW, Sackett DL, eds. Compliance in Health Care. Baltimore, Md: Johns Hopkins University Press; 1979
46. Keller MB, Lavori PW, Mueller TI, et al. Time to recovery, chronicity, and levels of psychopathology in major depression: a five-year prospective follow-up of 431 subjects. Arch Gen Psychiatry 1992;49:809-816
47. Lavori PW, Keller MB, Scheftner W, et al. Recurrence after recovery in unipolar MDD: an observational follow-up study of clinical predictors and somatic treatment as a mediating factor. International Journal of Methods in Psychiatry Research. In press
48. Keller MB, Shapiro RW, Lavori PW, et al. Relapse in major depressive disorder: analysis with life tables. Arch Gen Psychiatry 1982;39:911-915
49. NIMH Consensus Development Conference Statement. Mood disorders: pharmacologic prevention of recurrence. Am J Psychiatry 1985;142: 469-476
50. Belsher G, Costello CG. Relapse after recovery from unipolar depression: a critical review. Psychol Bull 1988;104:84-96
51. Prien RF, Kupfer DJ, Mansky PA, et al. Drug therapy in the prevention of recurrences in unipolar and bipolar affective disorders: report of the NIMH Collaborative Study Group comparing lithium carbonate, imipramine, and a lithium carbonate-imipramine combination. Arch Gen Psychiatry 1984;41:1096-1104
52. Frank E, Kupfer DJ, Perel JM, et al. Three-year outcomes for maintenance therapies in recurrent depression. Arch Gen Psychiatry 1990;47: 1093-1099
53. Kupfer DJ, Frank E, Perel JM, et al. Five-year outcome for maintenance therapies in recurrent depression. Arch Gen Psychiatry 1992;49:769-773
54. Kapur S, Mieczkwoski T, Mann JJ. Antidepressant medications and the relative risk of suicide attempt and suicide. JAMA 1992;268:3441-3445
55. Robins LN, Kulbok PA. Methodologie strategies in suicide. In: Mann J, Stanley M, eds. Psychology of Suicide Behavior. Ann N Y Acad Sci 1986;487:1-15
56. Phillips SD, Brent J, Kulig K, et al. Fluoxetine versus tricyclic antidepressants: a prospective multicenter study of antidepressant drug overdoses. Ann Emerg Med. In press
57. Palmer CS, Revicki DA, Halpern MT, et al. The cost of suicide and suicide attempts in the United States. Clin Neuropharmacol 1995;18:S25-S33
58. Torrance GW. Measurement of health utilities for economic appraisal: a review. Journal of Health Economics 1986;5:1-30
59. Torrance GW, Feeny D. Utilities and quality-adjusted life years. Int J Technol Assess Health Care 1989;5:559-575
60. Furlong W, Feeny D, Torrance GW, et al. Guide to Design and Development of Health-State Utility Instrumentation. Centre for Health Economics and Policy Analysis. Hamilton, Ontario: McMaster University; 1990
61. Laupacis A, Feeny D, Detsky S, et al. How attractive does a new technology have to be to warrant adoption and utilization: tentative guidelines for using clinical and economic evaluations. Can Med Assoc J 1991;146: 769-773
62. Sturm R, Wells KB. How can care for depression become more cost-effective? JAMA 1995;273:51-58
63. Simon G, Ormel J, Vonkorff M, et al. Health care costs associated with depressive and anxiety disorders. Am J Psychiatry 1995;152:352-357
64. Sclar DA, Robison LM, Skaer TL, et al. Antidepressant pharmacotherapy: economic evaluation of fluoxetine, paroxetine and sertraline in a health maintenance organization. J Int Med Res 1995;23:395-412
65. Gold MR, Siegal JE, Russell LB, et al, eds. Cost-Effectiveness in Health and Medicine. New York, NY: Oxford University Press; 1996